Blueprint Medicines Corporation (BPMC) is focused on developing transformational precision medicines to address genomically defined cancers and rare diseases.The company’s lead drug, Ayvakit/Ayvakyt (avapritinib), a kinase inhibitor, is approved for three rare cancer indications, both in the United States and the EU. The drug is approved for treating adults with PDGFRA Exon 18 mutant gastrointestinal stromal tumors, adults with advanced systemic mastocytosis and adults with indolent systemic mastocytosis (S ...

Blueprint Medicines (BPMC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual i ...

Third Quarter 2023 Financial Results Not for promotional use Agenda AYVAKIT PERFORMANCE Q3 2023 FINANCIAL PERFORMANCE Kate Haviland Chief Executive Officer Christy Rossi Chief Operating Officer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidate ...

Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Becker Hewes - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Peter Lawson - Barclays David Lebowitz - Citi Chris Raymond - Piper Sandler Matt Biegler - Oppenheimer I'll now turn it over to Jenna Cohen Vice President of Investor Relations. I'll now hand the call over to ...

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of ...

9 Second Quarter 2023 Financial Results AUGUST 2, 2023 INTRODUCTION AYVAKIT PERFORMANCE KEY PORTFOLIO MILESTONES Q2 2023 FINANCIAL PERFORMANCE Not for promotional use Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candi dates ...

Our execution across a diverse set of value drivers in the first half of this year has set us on a strong trajectory for continued success moving into the second half of 2023. Our number one priority will continue to be driving revenue acceleration with the launch of AYVAKIT and SM. While we also progress our pipeline of programs addressing some of the most important and exciting biological targets in oncology and allergy immunology that have the potential to impact large number of patients globally. While ...

Table of Contents The Company evaluated the Zai Lab agreement to determine whether it is a collaborative arrangement in the scope of ASC 808. The Company concluded that the Zai Lab agreement is a collaborative agreement under ASC 808 as both parties are active participants in the clinical trials and are exposed to significant risks and rewards of those activities under the Zai Lab agreement. The Company determined that the Zai Lab agreement contained two material components: (i) licenses granted to Zai Lab ...

Becker Hewes Operator Becker Hewes Following ASCO, we will continue enrollment in monotherapy cohorts and in parallel continued dose escalation of the combination of ribociclib in breast cancer patients. Second, we have our initial clinical data disclosure for BLU-451 in EGFR exon 20 mutant non-small cell lung cancer. These data will show safety and early clinical activity including evidence of CNS activity, that reinforced best-in-class potential for BLU-451. Thanks Becker. Earlier this morning, we've repo ...

4. Marketable Securities | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------|-------|--------------------|-------------------|-------|-----------------------|-------|--------------| | thousands): \nMarch 31, 2023 | | Amortized \nCost | Unrealized \nGain | | Unrealized \nLosses | | Fair \nValue | | Marketable securities, available-for-sale: | | | | | | | | | U.S. government agency securities | $ | 314,891 | | 28 | (2,117) | $ | 312,802 | | U.S. treasury obligat ...